Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways

P. Rogliani (Rome, Italy), M. Matera (Naples, Italy), E. Puxeddu (Rome, Italy), F. Cavalli (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy)

Source: International Congress 2019 – Advances in COPD pharmacology
Session: Advances in COPD pharmacology
Session type: Poster Discussion
Number: 2032
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Rogliani (Rome, Italy), M. Matera (Naples, Italy), E. Puxeddu (Rome, Italy), F. Cavalli (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy). Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways. 2032

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007



Beclomethasone, formoterol and glycopyrronium: synergy of dual and triple combinations in an ex vivo model of COPD exacerbation
Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies
Year: 2021


Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids
Source: Eur Respir J 2002; 19: 182-191
Year: 2002



Combination therapy with maintenance budesonide and formoterol in COPD
Source: Eur Respir J 2004; 24: 1070
Year: 2004


Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018




Effect of fluticasone and formoterol combination therapy on airway remodeling
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011


Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 14s
Year: 2005

LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015


Beclomethasone, formoterol and glycopyrronium: effect on an ex vivo model of COPD exacerbation
Source: Virtual Congress 2020 – Scientific advances in airway pharmacology
Year: 2020


Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Source: Eur Respir J 2001; 18: 262-268
Year: 2001



Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002

Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients
Source: Annual Congress 2010 - COPD: management
Year: 2010


Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012

Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010